Currently, although several novel drugs, such as RAS blockers, SGLT2 inhibitors, and MRAs, have shown clinical benefits for DKD, the current treatment options still have a limited ability to prevent the progression of kidney disease and reduce the risk of complications and death in DKD patients. This evidence concerns the gene SLC5A2 and kidney disorder.